Mobile App for ARFID Treatment
This study is developing and testing a mobile app called mCBT-AR, which delivers an 8-week virtual treatment for Avoidant/Restrictive Food Intake Disorder (ARFID). ARFID is an eating disorder where people avoid or restrict certain foods. The goal is to make treatment for ARFID more accessible and affordable. Researchers will measure how much your ARFID symptoms and food neophobia (fear of new foods) change from the beginning to the end of the 8-week program. This study plans to enroll 60 adults between 18 and 55 years old who have ARFID, live in the U.S., speak English, and have a smartphone with internet access. The current status of the study is unclear.
- Study design
- This is an interventional study planning to enroll 60 participants. It is testing a mobile app for ARFID treatment.
- What's involved
- You would participate in an 8-week virtual treatment program delivered via a mobile application. Your ARFID symptoms and food neophobia would be measured weekly.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progress will be measured at the final session, which occurs an average of eight weeks after you start the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Development and Testing of a Mobile App to Scale Delivery of Cognitive-behavioral Therapy for Avoidant/Restrictive Food Intake Disorder
At a glance
Conditions
NCT06898177
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Massachusetts General Hospital
Boston, Massachusettsno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Pica, ARFID, and Rumination Disorder Interview - ARFID Questionnaire (PARDI-AR-Q)Change from baseline (assessed at study entry) to final session, which occurs an average of eight weeks after baseline (measured at weekly study treatment sessions)
The PARDI-AR-Q is a 32-item self-report measure based on the Pica, ARFID, and Rumination Disorder Interview that assesses ARFID diagnostic criteria and the presence and severity of each ARFID profile. Severity scores for each profile range from 0-6, with higher scores indicating greater severity.
- Food Neophobia Scale (FNS)Change from baseline (assessed at study entry) to final session, which occurs an average of eight weeks after baseline (measured at weekly study treatment sessions)
The Food Neophobia Scale is a 6-item measure that measures reluctance to try new foods. Scores range from 7-42. Higher scores on the FNS are indicative of greater behavioral responses to novel foods.